Company intelligence / Profile preview

TomegaVax

Portland, Oregon, United States

Ownership: Private
Development stage: Other

Overview

TomegaVax was a biotechnology company focused on developing a unique vaccine platform using Cytomegalovirus (CMV) as a vector. Founded by researchers from Oregon Health & Science University, the company's technology aims to elicit a potent and sustained T-cell response to combat chronic infectious diseases and cancer. Its lead programs targeted HIV, Hepatitis B, and Tuberculosis. In 2016, TomegaVax was acquired by Vir Biotechnology, serving as a foundational component of Vir's infectious disease pipeline.

Therapeutic areas: Infectious Diseases
Modalities: VaccineViral vector
Industry: Biotech

Partnerships

Oregon Health & Science University

Beyond the preview

Go deeper on TomegaVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TomegaVax.

Explore the full profile